The company is executing on simple CBD extraction business strategies to sustain its primary biopharmaceutical development objectives.
DALLAS, Aug. 16, 2019 (GLOBE NEWSWIRE) — via OTC PR WIRE — Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today confirmed a scheduled CEO update to be published next week on Tuesday, August 20th, 2019 to provide shareholders with the latest updates on the company’s Cannabis Extract Biopharmaceutical developments.
“KALY is executing on a number of business lines from straight commercial CBD extraction from client hemp crops to the infusion of CBD into various consumer food products,” explained Company CEO, Frederick Ferri. “We are executing on these simple CBD extraction business strategies to sustain our primary biopharmaceutical development objectives. Next week, on Tuesday, when I provide shareholders with the latest updates on our cannabis extract biopharmaceutical developments, it is my intention to remind the market that we are first and foremost a cannabis extraction biopharmaceutical development company with solutions on par with, if not superior to, those of GW Pharmaceuticals. I’ve said it before and I’ll say it again, Doctors involved in research with our extracts have given me feedback that our extracts are superior to those of GW Pharmaceuticals.”
KALY owns and operates a US Patented Cannabis Extraction Process utilized primarily on discovering, developing and commercializing novel therapeutics from a proprietary cannabinoid product platform in a broad range of disease areas.
In the fourth quarter of last year, 2018, KALY acquired NCM Biotech (NCMB). In NCMB’s four years of operations, the company has established a leading position in the development of plant-derived cannabinoid therapeutics through a proven drug discovery and patented development process.
The resulting intellectual property portfolio and the established regulatory and manufacturing expertise have created a significant opportunity. KALY has a deep pipeline of cannabinoid product candidates including four distinct compounds. KALY has completed the first stage of clinical development and testing for a Chronic Obstructive Pulmonary Disease (COPD) therapy and is currently conducting phase one development and trials for compounds targeting Cancer Pain Management, Type 2 Diabetes and Epilepsy.
Next week, CEO Frederick Ferri will share the latest developments on the company’s biopharmaceutical developments.KALY is not relying on its biopharmaceutical development strategy alone to insure the company’s long-term success. With the popularity of cannabis extracts for infusion into various consumer products, KALY’s patented extraction process offers arguably the highest quality extract to the infusion market. KALY, through partnership and independently, has also introduced to market a number of CBD infused consumer food products. Drawing on KALY’s patented cannabis extraction expertise, the company has recently announced $15 million worth of extraction contracts with hemp farming operations.To learn more about the company visit https://www.kali-extracts.com/
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and as such, may involve risks and uncertainties. These forward looking statements relate to, amongst other things, current expectation of the business environment in which the company operates, potential future performance, projections of future performance and the perceived opportunities in the market.
The company’s actual performance, results and achievements may differ materially from the expressed or implied in such forward-looking statements as a result of a wide range of factors.